Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 763-770

  Kalantarian, Pardis ^a,b   Najafabadi, Abdolhosein Rouholamini ^a   Haririan, Ismaeil ^b   Vatanara, Alireza ^a   Yamini, Yadollah ^c   Darabi, Majid ^a   Gilani, Kambiz ^a  

^a Aerosol Research Laboratory   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

5 Fluorouracil; Lung cancer; Nanoparticles; Supercritical antisolvent

Indexed keywords

ACETONE; ALCOHOL; CARBON DIOXIDE; DICHLOROMETHANE; FLUOROURACIL; METHANOL; NANOPARTICLE; ANTINEOPLASTIC AGENT; SOLVENT;

AEROSOL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRY POWDER; INHALATIONAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; LUNG CANCER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; PRECIPITATION; PROCESS OPTIMIZATION; SOLVENT EFFECT; SUPERCRITICAL FLUID; ANIMAL; ATOMIC FORCE MICROSCOPY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; LUNG; LUNG TUMOR; METHODOLOGY; NANOMEDICINE; POWDER; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL FLUID CHROMATOGRAPHY; ULTRASTRUCTURE; X RAY DIFFRACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; LUNG; LUNG NEOPLASMS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POWDERS; SOLVENTS; X-RAY DIFFRACTION;

EID: 79952116605     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S12415     Document Type: Article

References (35)

1. American cancer society. Cancer facts and figures, 2008. Oakland: American Society; 2008:2-16.
2. Maillet A, Congy-Jolivet N, Le Guellec S. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res. 2008;25: 1318-1326.
3. Myrdal G, Lamberg K, Lambe M. Regional differences in treatment and outcome in non-small cell lung cancer: A population-based study. Lung Cancer. 2009;63:16-22.
4. Provencio M, Camps C, Alberola V. Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer. 2009;66:103-106.
5. Gagnadoux F, Pape AL, Lemarie E. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26: 657-661.
6. Hershey AE, Kurzman ID, Forrest LJ. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res. 1999;5:2653-2659.
7. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Pharmacol. 1996; 42:697-706.
8. He YC, Chen JW, Cao J, et al. Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats. World J Gastroenterol. 2003;9:1795-1798.
9. Yano T, Yamazaki K, Maruyama R. Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer - LOGIK 0601 study. Lung Cancer. 2010; 67:184-187.
10. Sharma S, White D, Imondi AR. Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19:1839-1847.
11. Hitzman CJ, Elmquist WF, Wattenberg LW. Development of a respirable, sustained release nicrocarrier for 5-fluorouracil I: In-vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci. 2006;95:1114-1126.
12. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipidcoated nanoparticles. J Pharm Sci. 2006;95:1196-1211.
13. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In-vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci. 2006;95: 1127-1143.
14. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29:196-212.
15. Dhumal RS, Biradar SV, Paradkar AR, et al. Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary delivery. Int J Pharm. 2009;386:129-137.
16. Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. Curr Opin Solid State Mater Sci. 2003;7: 371-383.
17. Ginty J, Whitaker MJ, Shakesheff KM, et al. Drug delivery goes supercritical. Materials Today. 2005;8:42-48.
18. Kim M, Jin S, Kim J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical anti-solvent (SAS) process. Eur J Pharm Pharmacol. 2008; 69:454-465.
19. Najafabadi AR, Vatanara A, Gilani K. Formation of salbutamol sulphate microparticles using solution enhanced dispersion by supercritical carbon dioxide. DARU. 2005;13:1-6.
20. Vatanara A, Najafabadi AR, Gilani KA, et al. Design for screening of the operational variables in the formation of salbutamol sulphate particles by supercritical anti-solvent. J Supercritical Fluids. 2007;40: 111-116.
21. Zeng XM, Tee SK, Martin GP. Effect of mixing procedure and particle size distribution of the carrier particle on the deposition of salbutamol sulphate from dry powder inhaler formulations. In: Proceedings of Drug Delivery to the Lungs VII. London: The Aerosol Society; 1996.
22. Giry K, Pean JM, Giraud L. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. Int J Pharm. 2006;321:162-166.
23. Lucas P, Clarke MJ, Anderson K, Tobyn MJ, Staniforth JN. The role of fine particle excipients in pharmaceutical dry powder aerosols. In: Dalby RN, Byron PR, Farr ST, editors. Respiratory Drug Delivery. Buffalo Grove, IL: Interpharm Press Inc; 1998.
24. Young S, Traini D, Jones MD. The influence of dose on the performance of dry powder inhalation systems. Int J Pharm. 2005;296: 26-33.
25. Gallagher PM, Coffey MP, Krukonis VJ, et al. Gas antisolvent recrystallization: New process to recrystallize compounds insoluble in supercritical fluids. In: Johnston K, Penninger J, editors. ACS Symposium Series 406. Supercritical Fluid Science and Technology. Washington, DC: American Chemical Society. 1989.
26. Dukhin SS, Shen Y, Dave R, et al. Droplet mass transfer, intradroplet nucleation and submicron particle production in two-phase flow of solvent-supercritical antisolvent emulsion. Coll Surf A. 2005;261: 163-176.
27. Stievano M, Elvassore N. High-pressure density and vapor-liquid equilibrium for the binary systems carbon dioxide-ethanol, carbon dioxide-acetone and carbon dioxide-dichloromethane. J Supercritical Fluids. 2005;33:7-14.
28. Geiser M, Schurch S, Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J Appl Physiol. 2003;94:1793-1801.
29. Wattenberg LW, Wiedmann TS, Estensen RD. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 2004;64:2347-2349.
30. Tatsumura TK, Tsujimoto M, Kitagawa M. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: Fundamental and clinical. Br J Cancer. 1993;68: 1146-1149.
31. Hwang SM, Kim DD, Chung SJ. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release. 2008;129:100-106.
32. Byron PR. Prediction of drug residence time in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci.1986; 75:433-438.
33. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002;19:425-498.
34. Corrigan DO, Corrigan OI, Healy AM. Physicochemical and in-vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm. 2006;322:22-30.
35. Yanga W, Peters JI, Williams RO. Inhaled nanoparticles - A current review. Int J Pharm. 2008;356:239-247.